Home » Stocks » FREQ

Frequency Therapeutics, Inc. (FREQ)

Stock Price: $38.73 USD 2.93 (8.18%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 1.31B
Revenue (ttm) 31.74M
Net Income (ttm) -21.81M
Shares Out 33.07M
EPS (ttm) -10.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $38.73
Previous Close $35.80
Change ($) 2.93
Change (%) 8.18%
Day's Open 35.97
Day's Range 34.57 - 39.80
Day's Volume 214,094
52-Week Range 14.65 - 40.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 5 days ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Business Wire - 2 weeks ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Business Wire - 1 month ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Zacks Investment Research - 1 month ago

Frequency Therapeutics (FREQ) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 1 month ago

Find Strong Stocks with this New Analyst Coverage Screener

Other stocks mentioned: ODP, XPER
Business Wire - 1 month ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Business Wire - 2 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Seeking Alpha - 2 months ago

Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the...

Business Wire - 2 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage ...

Business Wire - 3 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage ...

Business Wire - 4 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage ...

Seeking Alpha - 4 months ago

Frequency Therapeutics Has A Strong Scientific Rationale And An Upcoming Binary Catalyst

Business Wire - 4 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

Business Wire - 4 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

Business Wire - 5 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

InvestorPlace - 5 months ago

These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on ...

Other stocks mentioned: CASI, FDX, GES, LEVI
Benzinga - 5 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: FDX, GES
Zacks Investment Research - 6 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: APLT, GRBK, KELYA
Business Wire - 6 months ago

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc.

Seeking Alpha - 7 months ago

Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising

The Motley Fool - 10 months ago

While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.

Other stocks mentioned: APRE, VIE, VIR
The Motley Fool - 1 year ago

Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares in the open market?

Other stocks mentioned: APRE, VIE
Benzinga - 1 year ago

Frequency Therapeutics (NASDAQ: FREQ) made its public debut Thursday morning, opening at $11.20 after being priced at $14 per share.

About FREQ

Frequency Therapeutics, a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 3, 2019
CEO
David L. Lucchino
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
FREQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 47.00, which is an increase of 21.35% from the latest price.

Price Target
$47.00
(21.35% upside)
Analyst Consensus: Buy